arrow
H

Heike Kölbel

University Duisburg-Essen
H指数:23
被引数:1,883

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

德国、奥地利和瑞士关于使用onasemnogene abeparvovec进行脊髓性肌萎缩基因治疗的德尔菲共识——第二部分——基于专家的建议:副作用监测和管理

2026-08-270
PRE
Beyond distal arthrogryposis: refining the phenotypic landscape of PIEZO2-related disorders

超越远端关节挛缩症:精炼PIEZO2相关疾病的表型景观

Brain
IF11.7
2026-07-240
OAAI
Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland—part I—systematic literature review and existing evidence

德国、奥地利和瑞士关于Onasemnogene Abeparvovec治疗脊髓性肌萎缩基因疗法的德尔菲共识——第一部分——系统文献综述与现有证据

2025-11-240
OA
Unveiling MYH2-related myopathy: Histological-genetic insights from a case series and systematic review

揭示MYH2相关肌病:来自病例系列和系统综述的组织学-遗传学见解

2025-11-180
OA
A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy

SAPPHIRE临床试验的简明语言摘要,该试验研究apitegromab在儿童和年轻成人脊髓性肌萎缩症患者中的应用。

2025-11-130
OAAI
Phenotypic intrafamilial variability of 5q-associated spinal muscular atrophy: A systematic multicentre sibling study

5q相关脊髓性肌萎缩症的表型家族内变异性:一项系统性多中心同胞研究

2025-09-120
PRE
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial

阿皮特格罗玛ab在非行走型2型或3型脊髓性肌萎缩症中的安全性与有效性(SAPPHIRE研究):一项III期、双盲、随机、安慰剂对照试验

2025-08-130
PRE
Deciphering DST-associated disorders: biallelic variants affecting DST-b cause a congenital myopathy

解析DST相关疾病:影响DST-b的双等位基因变异导致先天性肌病

Brain
IF11.7
2025-06-110
PRE
Blood biomarker fingerprints in a cohort of patients with CHRNE-related congenital myasthenic syndrome
2025-02-130
OAAI
DNA-binding affinity and specificity determine the phenotypic diversity in BCL11B-related disorders
2025-02-010
OAAI
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial
2024-12-010
PRE
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy
2024-06-0112
PRE